IQWiG’s First Cost-Effectiveness Review Could Take Drug HTA To New Frontiers
This article was originally published in The Pink Sheet Daily
Germany’s reimbursement watchdog IQWiG’s first cost-effectiveness analysis uses four antidepressants as test case and finds they are overpriced.
You may also be interested in...
The decision by the German pharmaceutical arbitration committee to include countries such as Greece in a final pricing mechanism will cut German prices and may have a Europe-wide effect.
Sweden has been offering joint scientific advice to drug developers via a collaborative project between the country's reimbursement authority (TLV) and the Medical Products Agency (MPA).
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.